Arvinas to present ARV-393 lymphoma trial data at ASH meeting

Arvinas will present preliminary Phase 1 data for investigational oral BCL6 degrader ARV-393 at the American Society of Hematology Annual Meeting on December 14, 2026. The presentation will include safety, pharmacokinetics and pharmacodynamics data from all patients, plus preliminary efficacy results for patients with T-cell lymphomas; the article reports no study results yet.

Analysis

The December readout is a near-term binary catalyst for ARVN, but a conference presentation date is not itself evidence of clinical progress. In Phase 1, small cohorts and short follow-up can make early response rates look more decisive than they are; durability, dose-limiting toxicity, and exposure/target-engagement consistency should carry more weight than a headline response count. A key diligence point is the planned efficacy subset: the announcement specifies T-cell lymphoma patients while the drug targets BCL6, so confirm the actual histologies, BCL6 rationale, and whether the observed responses are attributable to the intended mechanism before extrapolating to broader NHL. The combination study with glofitamab is a separate development path and should not be treated as validated by monotherapy results.

Over the next 1–3 months, the stock’s reaction will likely depend on response quality and tolerability relative to the small-study caveats, with further clinical development and competitive differentiation playing out over 6–18 months. The contrarian point: investors may overvalue any early activity as platform validation, while underweighting safety, durability, and the challenge of translating a monotherapy signal into a differentiated treatment. Conversely, clean PK/PD plus consistent activity across relevant B-cell lymphoma subtypes could support a meaningful repricing. No company-specific valuation or consensus expectations are provided, so avoid assuming the catalyst is mispriced.

Key Decisions for Investors

• No pre-readout directional position based on the announcement alone. Put ARVN on the December 14 catalyst watchlist and verify the poster’s cohort sizes, histologies, dose levels, follow-up, response criteria, safety profile, and evidence of target engagement.
• Consider a small, defined-risk long only after the data show tolerable dosing and responses that are clinically interpretable across relevant B-cell lymphoma patients—not solely an isolated response or an unclear T-cell lymphoma subset. Size for Phase 1 data risk; do not infer a price target from preliminary results.
• If data are weak, narrow, or materially limited by toxicity, avoid buying an initial bounce and reassess ARVN’s clinical-asset risk versus a broad biotech proxy such as XBI; a relative underperformance trade is only actionable if liquidity and borrow are adequate.
• Falsifiers for a bullish interpretation: responses fail to persist with follow-up, activity is confined to a very small or biologically ambiguous subgroup, tolerability prevents useful exposure, or subsequent updates do not advance a credible dose and cohort-expansion plan.